STOCK TITAN
  1. Home
  2. Sec-filings
  3. INCY
  4. [Form 4] Incyte Genomics Inc Insider Trading Activity

[Form 4] Incyte Genomics Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock INCY logo
Incyte Corp

NASDAQ:INCY

INCY Rankings

#1110 Ranked by Market Cap
N/A Ranked by Dividends

INCY Latest News

Jul 10, 2025
Incyte to Report Second Quarter Financial Results
Jul 2, 2025
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 26, 2025
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
Jun 20, 2025
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
Jun 18, 2025
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

INCY Latest SEC Filings

Jul 16, 2025
[144] Incyte Genomics Inc SEC Filing
Jul 16, 2025
[144] Incyte Genomics Inc SEC Filing
Jul 16, 2025
[Form 4] Incyte Genomics Inc Insider Trading Activity
Jul 16, 2025
[Form 4] Incyte Genomics Inc Insider Trading Activity
Jul 16, 2025
[Form 4] Incyte Genomics Inc Insider Trading Activity

INCY Stock Data

13.10B
189.32M
1.99%
96.76%
3.02%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON